Q2 EPS Estimates for Prime Medicine Lifted by HC Wainwright

Prime Medicine, Inc. (NASDAQ:PRME) – Equities research analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for Prime Medicine in a research note issued to investors on Monday, June 29th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($0.28) per share for the quarter, up from their previous estimate of ($0.29). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Prime Medicine’s Q3 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.17) EPS, Q1 2027 earnings at ($0.22) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.23) EPS, Q4 2027 earnings at ($0.23) EPS and FY2027 earnings at ($0.90) EPS.

Several other equities analysts have also commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Prime Medicine in a research report on Wednesday, June 3rd. Citigroup reiterated a “market outperform” rating on shares of Prime Medicine in a research note on Monday, June 22nd. Oppenheimer began coverage on shares of Prime Medicine in a research report on Thursday, March 12th. They set an “outperform” rating and a $11.00 price target for the company. Wall Street Zen lowered shares of Prime Medicine from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 13th. Finally, The Goldman Sachs Group set a $6.00 price objective on shares of Prime Medicine in a report on Monday, June 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.53.

Prime Medicine Stock Down 0.8%

Shares of PRME stock opened at $3.69 on Wednesday. The stock has a market cap of $666.49 million, a price-to-earnings ratio of -3.00 and a beta of 2.31. The business’s fifty day moving average is $3.25 and its 200 day moving average is $3.57. Prime Medicine has a twelve month low of $2.28 and a twelve month high of $6.94.

Prime Medicine (NASDAQ:PRME) last announced its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.04). Prime Medicine had a negative return on equity of 188.82% and a negative net margin of 4,917.55%.The firm had revenue of $0.86 million during the quarter.

Institutional Investors Weigh In On Prime Medicine

Institutional investors have recently modified their holdings of the stock. Creative Planning purchased a new position in shares of Prime Medicine in the 2nd quarter worth about $25,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Prime Medicine during the 4th quarter valued at about $31,000. Royal Bank of Canada grew its position in Prime Medicine by 89.3% during the 1st quarter. Royal Bank of Canada now owns 9,254 shares of the company’s stock valued at $32,000 after purchasing an additional 4,365 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Prime Medicine during the 4th quarter valued at about $33,000. Finally, Glen Eagle Advisors LLC purchased a new position in Prime Medicine in the fourth quarter worth about $35,000. 70.37% of the stock is owned by hedge funds and other institutional investors.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.